Feed BBIO
BB

BridgeBio Pharma BBIO · NASDAQ

$74.95 +5.97% (+$4.22)

Market cap
$13.8B
Enterprise value
$15.6B
P/E
-
Forward P/E
-
PEG
-
P/S
20.0x
P/FCF
-
EV/EBITDA
-
ROIC
-61.8%
Gross margin
93.1%
Net margin
-100.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.97
Free float
85.5%

About the company

BridgeBio Pharma, Inc. is an American biotechnology company focused on the development and commercialization of innovative drugs for rare genetic diseases and cancer. Founded in 2015, the company's primary goal is to develop medicines that target the underlying genetic mechanisms causing various rare diseases. BridgeBio leverages advanced scientific technologies to identify genetic causes of diseases and then develops therapeutic options that may alleviate or even eliminate the symptoms of these conditions. The company has a portfolio of therapeutic programs in various stages of clinical trials and collaborates with other biotechnology companies and research institutions to accelerate the development of its products.

Sector

Healthcare

Industry

Biotechnology

CEO

Neil Kumar

Employees

839

Headquarters

Palo Alto

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 86% a year over the last 3 years.
  • What speaks for it: Analysts expect revenue to grow by 106% this fiscal year.
  • What to watch: It missed profit estimates 6 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy